Literature DB >> 33037053

Blurring the picture in leaky gut research: how shortcomings of zonulin as a biomarker mislead the field of intestinal permeability.

Lucas Massier1, Rima Chakaroun1, Peter Kovacs2, John T Heiker3.   

Abstract

Entities:  

Keywords:  celiac disease; gut inflammation; inflammatory bowel disease; intestinal permeability; irritable bowel syndrome

Mesh:

Substances:

Year:  2020        PMID: 33037053      PMCID: PMC8355880          DOI: 10.1136/gutjnl-2020-323026

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
With great interest we read the work by Talley et al 1 reporting the inadequacy of zonulin as a biomarker due to its failure to identify the irritable bowel syndrome, functional dyspepsia and non-coeliac wheat sensitivity. Zonulin as a biomarker is highly disputed.2 A recent study showed that zonulin-mediated intestinal barrier integrity is an important mechanism by which gut microbial dysbiosis affects the transition from asymptotic autoimmunity to inflammatory disease associated with increased circulating zonulin in patients with arthritis.3 In all of these studies, zonulin measurements are based on commercial ELISA. There is no doubt about the clinical relevance of studies addressing the relation between intestinal permeability and inflammatory diseases. Zonulin, precisely pre-haptoglobin 2 (preHP2), was identified as a human homologue to a second Vibrio cholerae enterotoxin regulating tight junction permeability and subsequently has gained much attention as a potential biomarker for intestinal permeability.4 However, the commercial ELISAs very frequently used to measure zonulin were produced using the first published sequence, which later has been shown to be unrelated to the zonulin protein.4 These developments have resulted in the following two major critical yet widely overlooked issues.

Commercially available ELISAs do not measure zonulin

The shortcomings of the commercial ELISA have been demonstrated in independent work and have been discussed previously.5 6 Measurements using these commercial ELISA do not reflect actual zonulin levels, but concentrations of unknown proteins. Consequently, this has to preclude scientists from drawing conclusions on the role and importance of zonulin in the context of intestinal permeability and related diseases based on these ELISA measurements, both positive and negative. This, also retrospectively, applies to numerous studies reporting findings relying on the commercial ELISA kits.6 Furthermore, these zonulin ELISA measurements only poorly correlate with functional gut permeability as assessed by, for example, lactulose mannitol test (table 1).
Table 1

Studies using zonulin ELISA and correlations with intestinal permeability

StudyYearZonulin kitNCorrelationCitation
Halasa et al 2019IDK38R=0.11, p>0.05 8
Linsalata et al 2018IDK71R=0.17, p>0.05 9
Kuzma et al 2020IDK(distributed by ALPCO) 24R=0.033, p=0.79 10
Studies using zonulin ELISA and correlations with intestinal permeability Importantly, this does not take away from zonulin/preHP2 as a regulator of intestinal permeability and does not rule out correlations of zonulin levels with intestinal barrier function.

Zonulin as pre-haptoglobin2 is not expressed in mice

Animal models of intestinal barrier dysfunction are highly useful for translational research, yet zonulin as preHP2 is not naturally expressed in mice. While haptoglobin is conserved in most mammals, the HP2 genotype is unique to humans. This renders measurements of serum zonulin in rodent models highly questionable and potentially misleading.3 Along these lines, differential ELISA signals obtained in mouse sera further indicate detection of unspecific and unknown proteins by the ELISA.3 For translational research, assessing zonulin levels in mouse models does only become relevant when using zonulin-specific assays in ‘humanised mice’ genetically modified to express human HP2, as has been previously described.7

Conclusion

Together, it has become obvious that using the commercial zonulin ELISA is neither adequate to measure intestinal permeability nor the postulated biomarker zonulin. Even more important, previously published results based on zonulin ELISA measurements have to be seen with great caution and do not establish a relation to the function of the protein zonulin/preHP2. New and specific detection methods and assays for zonulin/preHP2 are urgently needed to address the usefulness of zonulin as a biomarker for intestinal permeability. Until then, researchers are strongly encouraged to circumvent the unspecific measurement of zonulin and instead apply rigorous tests of intestinal permeability such as dual-sugar assays, and use immunohistochemistry and expression profiles of zonula occludens proteins.3
  10 in total

1.  Intraindividual Variation in Markers of Intestinal Permeability and Adipose Tissue Inflammation in Healthy Normal-Weight to Obese Adults.

Authors:  Jessica N Kuzma; Derek K Hagman; Gail Cromer; Kara L Breymeyer; Christian L Roth; Karen E Foster-Schubert; Sarah E Holte; David S Weigle; Mario Kratz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-12-20       Impact factor: 4.254

2.  Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity.

Authors:  Maria Raffaella Barbaro; Cesare Cremon; Antonio Maria Morselli-Labate; Antonio Di Sabatino; Paolo Giuffrida; Gino Roberto Corazza; Michele Di Stefano; Giacomo Caio; Giovanni Latella; Carolina Ciacci; Daniele Fuschi; Marianna Mastroroberto; Lara Bellacosa; Vincenzo Stanghellini; Umberto Volta; Giovanni Barbara
Journal:  Gut       Date:  2020-02-14       Impact factor: 23.059

3.  Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2.

Authors:  Amit Tripathi; Karen M Lammers; Simeon Goldblum; Terez Shea-Donohue; Sarah Netzel-Arnett; Marguerite S Buzza; Toni M Antalis; Stefanie N Vogel; Aiping Zhao; Shiqi Yang; Marie-Claire Arrietta; Jon B Meddings; Alessio Fasano
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-15       Impact factor: 11.205

4.  Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study.

Authors:  Michele Linsalata; Giuseppe Riezzo; Benedetta D'Attoma; Caterina Clemente; Antonella Orlando; Francesco Russo
Journal:  BMC Gastroenterol       Date:  2018-11-06       Impact factor: 3.067

5.  Exploiting the Zonulin Mouse Model to Establish the Role of Primary Impaired Gut Barrier Function on Microbiota Composition and Immune Profiles.

Authors:  Alba Miranda-Ribera; Maria Ennamorati; Gloria Serena; Murat Cetinbas; Jinggang Lan; Ruslan I Sadreyev; Nitya Jain; Alessio Fasano; Maria Fiorentino
Journal:  Front Immunol       Date:  2019-09-19       Impact factor: 7.561

6.  Assessing the Association of Elevated Zonulin Concentration in Stool with Increased Intestinal Permeability in Active Professional Athletes.

Authors:  Maciej Hałasa; Dominika Maciejewska; Karina Ryterska; Magdalena Baśkiewicz-Hałasa; Krzysztof Safranow; Ewa Stachowska
Journal:  Medicina (Kaunas)       Date:  2019-10-21       Impact factor: 2.430

7.  Zonulin in serum as a biomarker fails to identify the IBS, functional dyspepsia and non-coeliac wheat sensitivity.

Authors:  Nicholas J Talley; Gerald J Holtmann; Michael Jones; Natasha A Koloski; Marjorie M Walker; Grace Burns; Michael D E Potter; Ayesha Shah; Simon Keely
Journal:  Gut       Date:  2019-09-28       Impact factor: 23.059

8.  Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family.

Authors:  Lucas Scheffler; Alyce Crane; Henrike Heyne; Anke Tönjes; Dorit Schleinitz; Christian H Ihling; Michael Stumvoll; Rachel Freire; Maria Fiorentino; Alessio Fasano; Peter Kovacs; John T Heiker
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-05       Impact factor: 5.555

9.  Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems.

Authors:  Mary Ajamian; David Steer; Gennaro Rosella; Peter R Gibson
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

10.  Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis.

Authors:  Narges Tajik; Michael Frech; Oscar Schulz; Fabian Schälter; Sébastien Lucas; Vugar Azizov; Kerstin Dürholz; Franziska Steffen; Yasunori Omata; Andreas Rings; Marko Bertog; Aroldo Rizzo; Aida Iljazovic; Marijana Basic; Arnd Kleyer; Stephan Culemann; Gerhard Krönke; Yubin Luo; Klaus Überla; Udo S Gaipl; Benjamin Frey; Till Strowig; Kerstin Sarter; Stephan C Bischoff; Stefan Wirtz; Juan D Cañete; Francesco Ciccia; Georg Schett; Mario M Zaiss
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

  10 in total
  6 in total

1.  Correlation Between Zinc Nutritional Status with Serum Zonulin and Gastrointestinal Symptoms in Diarrhea-Predominant Irritable Bowel Syndrome: A Case-Control Study.

Authors:  Mahsa Rezazadegan; Maryam Soheilipour; Mohammad Javad Tarrahi; Reza Amani
Journal:  Dig Dis Sci       Date:  2022-01-06       Impact factor: 3.487

Review 2.  Role of the gut microbiome in three major psychiatric disorders.

Authors:  Jenny Borkent; Magdalini Ioannou; Jon D Laman; Bartholomeus C M Haarman; Iris E C Sommer
Journal:  Psychol Med       Date:  2022-05-04       Impact factor: 10.592

Review 3.  Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity.

Authors:  Yusuke Kinashi; Koji Hase
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

Review 4.  Impaired Intestinal Barrier and Tissue Bacteria: Pathomechanisms for Metabolic Diseases.

Authors:  Lucas Massier; Matthias Blüher; Peter Kovacs; Rima M Chakaroun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-09       Impact factor: 5.555

5.  In vitro Effects of Bacterial Exposure on Secretion of Zonulin Family Peptides and Their Detection in Human Tissue Samples.

Authors:  Ching Jian; Sonja Kanerva; Sami Qadri; Hannele Yki-Järvinen; Anne Salonen
Journal:  Front Microbiol       Date:  2022-04-14       Impact factor: 6.064

6.  Intestinal Permeability and Depression in Patients with Inflammatory Bowel Disease.

Authors:  Miorita Melina Iordache; Cristina Tocia; Mariana Aschie; Andrei Dumitru; Mihaela Manea; Georgeta Camelia Cozaru; Lucian Petcu; Sabina E Vlad; Eugen Dumitru; Anca Chisoi
Journal:  J Clin Med       Date:  2022-08-30       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.